ClinicalTrials.gg
CompletedNCT05897112Updated Jun 9, 2023

Comparative Efficacy of 10% Potassium Hydroxide Solution Versus Cryotherapy in Molluscum Contagiosum

A Phase 1 interventional study of Group A received cryotherpay and Group B received 10% Potassium Hydroxide Solution in Molluscum Contagiosum, sponsored by Combined Military Hospital Abbottabad. Completed at 1 site in Pakistan. Open to participants aged 4 Years to 12 Years. Per ClinicalTrials.gov, last updated 2023-06-09.

Sponsored by Combined Military Hospital Abbottabad · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 6 months after the study started (first participant enrolled Nov 2022, registered May 2023).
Phase
Phase 1
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
4 Years to 12 Years
Sex
All
01

Study summary

A total of sixty patients presented to the outpatient dermatology department of Combined military hospital (CMH) Abbottabad with signs of molluscum contagiosum clinically diagnosed meeting inclusion criteria were enrolled. Sample size was calculated using WHO sample size calculator. They were divided into two groups i.e Group A and Group B using lottery method. Patients in Group A were subjected to cryotherapy (liquid nitrogen gas) whereas patients in Group B patients were subjected to 10% potassium hydroxide solution for 3 weeks and were followed up at 2nd, 4th, 8th and 12th week for observing the progress of therapy in both groups on each follow up visit and ascertaining the efficacy respectively.

02

Conditions studied

  • Molluscum Contagiosum

Browse trials for

03

In context

Molluscum Contagiosum

22 studies on the registry are indexed under Molluscum Contagiosum; none are open to participants now.

This study's enrollment of 60 is below the median of 94 across 19 interventional studies indexed under Molluscum Contagiosum.

Browse Molluscum Contagiosum studies →

Lead sponsor

Combined Military Hospital Abbottabad is the lead sponsor of 25 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
4 Years to 12 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • clinical diagnosis of molluscum contagiosum having 3-20 lesion
  • no history of treatment before
  • willingness to participate (given by parents)

Exclusion criteria

Exclusion Criteria:

  • Patients with facial lesions
  • known immunodeficiency
  • tendency for hypertrophic scarring
  • known
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (actual)

Study arms

  • Active comparator
    Group A received cryotherapy

    Group A were subjected to weekly cryotherapy with a cotton stick dip ped in Liquid Nitrogen for 02 Freezes and Thaw Cycle of 07 seconds with each cycle 10 seconds apart for 3 weeks

    Drug: Group A received cryotherpay

  • Active comparator
    Group B received 10% Potassium Hydroxide Solution

    Group B applied 10% Potassium Hydroxide solution twice daily with the help of a cotton tip applicator until lesion showed signs of inflammation or clearance for 3 weeks

    Drug: Group B received 10% Potassium Hydroxide Solution

Interventions

  • DrugGroup A received cryotherpay

    Group A were subjected to weekly cryotherapy with a cotton stick dip ped in Liquid Nitrogen for 02 Freezes and Thaw Cycle of 07 seconds with each cycle 10 seconds apart for 3 weeks

  • DrugGroup B received 10% Potassium Hydroxide Solution

    Group B applied 10% potassium hydroxide aqueous solution twice daily with the help of a cotton tip applicator until lesion showed signs of inflammation or clearance for 3 weeks

06

What researchers measure

Primary outcomes

  1. Efficacy was assessed at 12th week by the clearance of lesion or not

    Final evaluation in terms of efficacy was done at the follow up visit in 12th week and the method was termed as effective (Yes) on achieving complete clearance of lesions confirmed on clinical \& physical examination of the affected areas by a consultant dermatologist using dermoscopy showing complete resolution of lesions. However, if lesions were not completely cleared at the end of 12th week, the treatment method was labelled as ineffective (No).

    Time frame: 12 weeks

07

Study locations

1 site
  • CMH Abbottabad
    Abbottābād, Khyber Pakhtunkhwa, Pakistan
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 9, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05897112
Lead sponsor
Combined Military Hospital Abbottabad
Responsible party
danyal sajjad (Principal Investigator, Combined Military Hospital Abbottabad) — Principal investigator
First posted
Jun 9, 2023
Start date
Nov 1, 2022
Primary completion
Apr 30, 2023
Completion
Apr 30, 2023
Last update
Jun 9, 2023

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion